Algert Global LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Algert Global LLC

$2.55 Billion
Q1 2024

A detailed history of Algert Global LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Algert Global LLC holds 19,810 shares of ARWR stock, worth $496,636. This represents 0.02% of its overall portfolio holdings.

Number of Shares

19,810

Previous 8,980 120.6%

Holding current value

$496,636

Previous $275,000 106.18%

% of portfolio

0.02%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$27.21 - $39.48 $294,684 - $427,568	10,830 Added 120.6%	19,810 $567,000
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $1.13 Million - $1.66 Million	-53,445 Reduced 85.61%	8,980 $275,000
Q3 2023 Nov 13, 2023	SELL	$26.2 - $36.08 $1.44 Million - $1.98 Million	-54,870 Reduced 46.78%	62,425 $1.68 Million
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $2.43 Million - $4 Million	96,675 Added 468.84%	117,295 $4.18 Million
Q1 2023 May 12, 2023	BUY	$23.68 - $38.51 $488,281 - $794,076	20,620 New	20,620 $524,000

Q3 2022 Nov 15, 2022	BUY	$29.63 - $48.31 $436,835 - $712,234	14,743 Added 24.28%	75,462 $2.49 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $737,935 - $1.34 Million	26,554 Added 77.72%	60,719 $2.14 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $868,113 - $1.53 Million	21,911 Added 178.81%	34,165 $1.57 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $149,407 - $212,215	-2,572 Reduced 17.35%	12,254 $812,000
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $865,541 - $1.26 Million	14,826 New	14,826 $926,000

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.65B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Arrowhead Pharmaceuticals, Inc. Transaction History